Bevacizumab biosimilar - mAbixience

Drug Profile

Bevacizumab biosimilar - mAbixience

Alternative Names: BEVZ92; MB02

Latest Information Update: 08 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator mAbxience
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer
  • No development reported Cancer

Most Recent Events

  • 04 Oct 2017 mAbxience plans the STELLA phase III trial for Non-small cell lung cancer(Late-stage disease) in Brazil, Bulgaria, Chile, Georgia, Greece, Hungary, India, Jordan, Lebanon, Malaysia, Mexico, Oman, Peru, Philippines, Russia, Serbia, South Africa, Thailand, Turkey and Ukraine(NCT03296163)
  • 03 Oct 2017 mAbxience plans a phase I trial in Healthy volunteers in United Kingdom (NCT03293654)
  • 06 Jun 2017 Pharmacokinetics data from a Phase I trial in Colorectal cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top